Last reviewed · How we verify
Immunotherapeutic GSK2302025A, different formulations — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Immunotherapeutic GSK2302025A, different formulations (Immunotherapeutic GSK2302025A, different formulations) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Immunotherapeutic GSK2302025A, different formulations TARGET | Immunotherapeutic GSK2302025A, different formulations | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Immunotherapeutic GSK2302025A, different formulations CI watch — RSS
- Immunotherapeutic GSK2302025A, different formulations CI watch — Atom
- Immunotherapeutic GSK2302025A, different formulations CI watch — JSON
- Immunotherapeutic GSK2302025A, different formulations alone — RSS
Cite this brief
Drug Landscape (2026). Immunotherapeutic GSK2302025A, different formulations — Competitive Intelligence Brief. https://druglandscape.com/ci/immunotherapeutic-gsk2302025a-different-formulations. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab